BR112018001451A2 - compostos úteis para a inibição de ror-gama-t - Google Patents

compostos úteis para a inibição de ror-gama-t

Info

Publication number
BR112018001451A2
BR112018001451A2 BR112018001451-6A BR112018001451A BR112018001451A2 BR 112018001451 A2 BR112018001451 A2 BR 112018001451A2 BR 112018001451 A BR112018001451 A BR 112018001451A BR 112018001451 A2 BR112018001451 A2 BR 112018001451A2
Authority
BR
Brazil
Prior art keywords
gamma
ror
inhibition
compounds useful
inhibitors
Prior art date
Application number
BR112018001451-6A
Other languages
English (en)
Other versions
BR112018001451B1 (pt
Inventor
Richard Morphy John
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of BR112018001451A2 publication Critical patent/BR112018001451A2/pt
Publication of BR112018001451B1 publication Critical patent/BR112018001451B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a presente invenção refere-se aos novos inibidores de ror gama-t e suas composições farmacêuticas: .
BR112018001451-6A 2015-09-09 2016-09-06 Compostos úteis para inibição de ror-gamma-t, seus usos, e composição farmacêutica BR112018001451B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562215929P 2015-09-09 2015-09-09
US62/215,929 2015-09-09
PCT/US2016/050374 WO2017044410A1 (en) 2015-09-09 2016-09-06 Compounds useful for inhibiting ror-gamma-t

Publications (2)

Publication Number Publication Date
BR112018001451A2 true BR112018001451A2 (pt) 2018-09-11
BR112018001451B1 BR112018001451B1 (pt) 2023-10-10

Family

ID=56940418

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018001451-6A BR112018001451B1 (pt) 2015-09-09 2016-09-06 Compostos úteis para inibição de ror-gamma-t, seus usos, e composição farmacêutica

Country Status (41)

Country Link
US (1) US9598431B1 (pt)
EP (1) EP3347360B1 (pt)
JP (1) JP6282789B1 (pt)
KR (1) KR102048780B1 (pt)
CN (1) CN108026112B (pt)
AR (1) AR105821A1 (pt)
AU (1) AU2016318593B2 (pt)
BR (1) BR112018001451B1 (pt)
CA (1) CA2994732C (pt)
CL (1) CL2018000558A1 (pt)
CO (1) CO2018002440A2 (pt)
CR (1) CR20180089A (pt)
CY (1) CY1122287T1 (pt)
DK (1) DK3347360T3 (pt)
DO (1) DOP2018000066A (pt)
EA (1) EA033882B1 (pt)
EC (1) ECSP18018793A (pt)
ES (1) ES2760992T3 (pt)
HK (1) HK1249901B (pt)
HR (1) HRP20192235T1 (pt)
HU (1) HUE047950T2 (pt)
IL (1) IL257202B (pt)
JO (1) JO3638B1 (pt)
LT (1) LT3347360T (pt)
MA (1) MA42776B1 (pt)
MD (1) MD3347360T2 (pt)
MX (1) MX2018002898A (pt)
MY (1) MY195903A (pt)
NZ (1) NZ739518A (pt)
PE (1) PE20181274A1 (pt)
PH (1) PH12018500504A1 (pt)
PL (1) PL3347360T3 (pt)
PT (1) PT3347360T (pt)
RS (1) RS59655B1 (pt)
SI (1) SI3347360T1 (pt)
SV (1) SV2018005647A (pt)
TN (1) TN2018000057A1 (pt)
TW (1) TWI597284B (pt)
UA (1) UA118824C2 (pt)
WO (1) WO2017044410A1 (pt)
ZA (1) ZA201800515B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110337440B (zh) * 2017-03-02 2021-08-03 伊莱利利公司 可用于抑制ROR-γ-t的化合物
PT3589637T (pt) * 2017-03-02 2021-06-02 Lilly Co Eli Compostos úteis para inibir ror-gamma-t
WO2018193297A1 (en) 2017-04-21 2018-10-25 Cadila Healthcare Limited Novel compounds as ror-gamma modulators
JP2020142989A (ja) * 2017-06-21 2020-09-10 Meiji Seikaファルマ株式会社 イミダゾール誘導体及びそれを含有する医薬
WO2022122740A1 (en) 2020-12-07 2022-06-16 Diaccurate Ror-gamma inhibitors for the treatment of ror-gamma-dependent cancer
WO2023232870A1 (en) 2022-05-31 2023-12-07 Immunic Ag Rorg/rorgt modulators for the treatment of virus infections like covid-19

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016913A1 (en) * 2003-08-19 2005-02-24 Pfizer Japan, Inc. Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders
JP3790250B2 (ja) * 2004-01-16 2006-06-28 新日鐵化学株式会社 両面導体ポリイミド積層体の連続製造方法
UA107943C2 (en) 2009-11-16 2015-03-10 Lilly Co Eli Compounds of spiropiperidines as antagonists of the orl-1 receptors
SI2501704T1 (sl) * 2009-11-16 2013-11-29 Eli Lilly Company Spojine spiropiperidina kot antagonisti oral-1 receptorja
KR101855471B1 (ko) * 2009-12-04 2018-05-09 선오비온 파마슈티컬스 인코포레이티드 다환형 화합물 및 이의 사용 방법
TWI582096B (zh) * 2011-12-06 2017-05-11 美國禮來大藥廠 用於酒精依賴及濫用處理之4',5'-二氫螺[哌啶-4,7'-噻吩并[2,3-c]哌喃]化合物
BR112014028017A2 (pt) * 2012-05-08 2017-06-27 Lycera Corp composto, composição farmacêutica, método para tratar um distúrbio, método para reduzir a quantidade il-17 em um indivíduo e método para inibir a atividade de ror
AU2013270036B2 (en) * 2012-05-31 2016-12-01 Phenex Pharmaceuticals Ag Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ROR(gamma)
WO2014026328A1 (en) * 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 3-cyclohexenyl substituted indole and indazole compounds as rorgammat inhibitors and uses thereof
WO2014179564A1 (en) 2013-05-01 2014-11-06 Vitae Pharmaceuticals, Inc. Thiazalopyrrolidine inhibitors of ror-gamma
JP6192836B2 (ja) 2013-07-30 2017-09-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Rorcモジュレーターとしてのアザインドール化合物
WO2015101928A1 (en) * 2013-12-31 2015-07-09 Aurigene Discovery Technologies Limited Fused thiophene and thiazole derivatives as ror gamma modulators

Also Published As

Publication number Publication date
CY1122287T1 (el) 2020-11-25
KR20180031777A (ko) 2018-03-28
BR112018001451B1 (pt) 2023-10-10
UA118824C2 (uk) 2019-03-11
CA2994732A1 (en) 2017-03-16
AR105821A1 (es) 2017-11-15
SI3347360T1 (sl) 2019-12-31
EP3347360B1 (en) 2019-10-23
IL257202B (en) 2020-02-27
EA201890364A1 (ru) 2018-08-31
EP3347360A1 (en) 2018-07-18
TWI597284B (zh) 2017-09-01
CA2994732C (en) 2020-06-30
MX2018002898A (es) 2018-06-18
ECSP18018793A (es) 2018-04-30
DOP2018000066A (es) 2018-03-30
EA033882B1 (ru) 2019-12-05
MA42776B1 (fr) 2020-02-28
IL257202A (en) 2018-03-29
WO2017044410A1 (en) 2017-03-16
PT3347360T (pt) 2020-01-07
HK1249901B (zh) 2020-06-19
MD3347360T2 (ro) 2020-03-31
LT3347360T (lt) 2020-01-27
CN108026112A (zh) 2018-05-11
PH12018500504A1 (en) 2018-09-24
MY195903A (en) 2023-02-27
US9598431B1 (en) 2017-03-21
PL3347360T3 (pl) 2020-04-30
SV2018005647A (es) 2018-07-23
NZ739518A (en) 2019-06-28
JO3638B1 (ar) 2020-08-27
PE20181274A1 (es) 2018-08-03
CL2018000558A1 (es) 2018-08-10
AU2016318593B2 (en) 2018-10-04
JP2018507203A (ja) 2018-03-15
CO2018002440A2 (es) 2018-07-10
ZA201800515B (en) 2019-06-26
KR102048780B1 (ko) 2019-11-27
TW201722964A (zh) 2017-07-01
CN108026112B (zh) 2020-04-10
JP6282789B1 (ja) 2018-02-21
US20170066781A1 (en) 2017-03-09
HRP20192235T1 (hr) 2020-03-20
RS59655B1 (sr) 2020-01-31
CR20180089A (es) 2018-02-27
ES2760992T3 (es) 2020-05-18
TN2018000057A1 (en) 2019-07-08
AU2016318593A1 (en) 2018-02-15
DK3347360T3 (da) 2020-01-02
HUE047950T2 (hu) 2020-05-28

Similar Documents

Publication Publication Date Title
CU20180001A7 (es) Derivados de oxopiridina sustituidos y procesos para su preparación
MX2018001990A (es) Composiciones que comprenden un inhibidor de p13k y un inhibidor de hdac.
BR112018001451A2 (pt) compostos úteis para a inibição de ror-gama-t
BR112017005266A2 (pt) inibidores de mk2 e uso dos mesmos
PH12016500895A1 (en) Substituted piperidyl-ethyl-pyrimidine as ghrelin o-acyl transferase inhibitor
CR20150541A (es) Compuestos y composiciones nuevos para la inhibición de fasn
BR112013028281A2 (pt) compostos e composições para inibição de nampt
PH12017502051A1 (en) TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF
BR112017008714A2 (pt) inibidores de bromodomínio
UY36204A (es) Derivados de insoindolina.
BR112018011633A2 (pt) inibidores de aza-benzimidazol de pad4
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
UY36221A (es) Derivados de isoindolinona
DK3240767T3 (da) Mikroindkapslede nitrifikationshæmmersammensætninger
CR20170050A (es) Compuestos de azetidiniloxifenilpirrolidina
BR112018006005A2 (pt) composto bicíclico e uso do mesmo para inibição de suv39h2
EA201790392A1 (ru) Фармацевтическая упаковка
BR112016023767A2 (pt) forma sólida, composição farmacêutica, compostos, métodos, composições e utilizações
BR112017022340A2 (pt) 2-tiopirimidinonas
BR112017008594A2 (pt) derivados de 2-(1,2,4-triazol-3-ilsulfanil)-n-1,3,4-tiadiazol-2-il acetamida que são úteis para o tratamento de diabetes inter alia
BR112017013507A2 (pt) Composições de inibidor de nitrificação micro- encapsuladas
BR112016024236A2 (pt) composições farmacêuticas compreendendo agentes antibacterianos
UY37009A (es) Formulaciones granuladas de giberelina
TH1501005409A (th) สารประกอบและองค์ประกอบแบบใหม่สำหรับการยับยั้ง fasn
BR112015023592A2 (pt) compostos orgânicos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/09/2016, OBSERVADAS AS CONDICOES LEGAIS